clinical trial · NCT06752876
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
Systemic Lupus ErythematosusLupusLupus ErythematosusLupus NephritisCB-010
brief summary
This is a Phase 1 study to evaluate the safety and efficacy of a single infusion of CB-010 in patients with refractory Systemic Lupus Erythematosus (SLE) with cohorts for lupus nephritis (LN) and extrarenal lupus (ERL).
started
Dec 1, 2027
primary completion
Apr 1, 2029
completion
Apr 1, 2029
last updated
Sep 19, 2025
detailed description
Participants enrolled can expect to be on the study for a total duration of approximately 2 years, during which there will be a screening period followed by a single administration of CB-010 and then 24 months of safety follow-up and monitoring.
official title
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol